Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK.
Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
Best Pract Res Clin Obstet Gynaecol. 2020 Apr;64:68-76. doi: 10.1016/j.bpobgyn.2019.10.007. Epub 2019 Nov 15.
Advances in therapeutics, including a wider use of biologics and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) have substantially improved the management of rheumatic diseases, resulting in more women with severe disease considering pregnancy. Every clinical rheumatologist has encountered a woman who wishes to have a pregnancy - or who presents already pregnant - and who values the importance of reliable information on rheumatic diseases and safety of medications in pregnancy. This chapter summarises current evidence and knowledge on the use of 'Medications in pregnancy and breastfeeding in women with rheumatic diseases' and considers paternal medication use at the time of conception.
治疗方法的进步，包括生物制剂和靶向合成疾病修正抗风湿药物（DMARDs）的更广泛应用，极大地改善了风湿性疾病的治疗管理，导致更多患有严重疾病的女性考虑怀孕。每位临床风湿病学家都曾遇到过一位想要怀孕的女性——或者已经怀孕的女性——她重视有关风湿性疾病的可靠信息以及怀孕期间药物安全性的重要性。本章总结了目前关于“风湿性疾病女性在妊娠和哺乳期使用药物”的证据和知识，并考虑了在受孕时父亲使用药物的情况。
